Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.58 |
| ▸ | METAP1 | P53582 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022661 | 1.00 | ACHE (0.58) | ACHEMETAP1TSHRCYP19A1ALDH1A1 | |
| SCHEMBL4221590 | 1.00 | ACHE (0.58) | ACHEMETAP1TSHRCYP19A1ALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL28512185 | 0.85 | ACHE (0.47) | ACHEMETAP1TSHRCYP19A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL28512188 | 0.85 | ACHE (0.44) | ACHEMETAP1TSHRCYP19A1ALDH1A1 | |
| SCHEMBL25001847 | 0.81 | CYP19A1 (0.47) | ACHETSHRCYP19A1ALDH1A1HSD17B10 | |
| SCHEMBL11523523 | 0.81 | ACHE (0.53) | ACHEMETAP1TSHRCYP19A1KDM4E | |
| SCHEMBL13337387 | 0.81 | S100A4 (0.53) | ACHECYP19A1ALDH1A1HBBHSD17B10 | |
| SCHEMBL6273471 | 0.80 | ACHE (0.49) | ACHEMETAP1TSHRCYP19A1ALDH1A1 | |
| SCHEMBL28525188 | 0.75 | ACHE (0.63) | ACHEMETAP1CYP19A1 | |
| SCHEMBL28509563 | 0.75 | ACHE (0.46) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478616-B1 | INDANES AND INDANONES AND THEIR USE IN PERFUMERY | GIVAUDAN SA (CH) | 2010-09-22 | — | — | EP | claimed |
| US-20050148493-A1 | Indanes and indanones and their use in perfumery | FLACHSMANN FELIX (CH) | 2005-07-07 | — | — | US | claimed |
| EP-1478616-A1 | INDANES AND INDANONES AND THEIR USE IN PERFUMERY | Givaudan SA (CH) | 2004-11-24 | — | — | EP | claimed |
| WO-2003072533-A1 | INDANES AND INDANONES AND THEIR USE IN PERFUMERY | GIVAUDAN SA (CH) | 2003-09-04 | — | — | WO | claimed |
| EP-1340741-A1 | Indane derivatives and their use in perfumery | Givaudan SA (CH) | 2003-09-03 | — | — | EP | claimed |
| CN-110352195-A | Catalyst | 博里利斯股份公司 | 2019-10-18 | — | — | CN | disclosed |
| US-10308607-B2 | Fucosidase inhibitors | HORIZON ORPHAN LLC (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190077756-A1 | FUCOSIDASE INHIBITORS | HORIZON ORPHAN LLC (US) | 2019-03-14 | — | — | US | disclosed |
| US-9951013-B2 | Fucosidase inhibitors | HORIZON ORPHAN LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951013-B2 | Fucosidase inhibitors | HORIZON ORPHAN LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170029376-A1 | FUCOSIDASE INHIBITORS | RAPTOR PHARMACEUTICALS INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029376-A1 | FUCOSIDASE INHIBITORS | RAPTOR PHARMACEUTICALS INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-7538243-B2 | Indanes and indanones and their use in perfumery | GIVAUDAN SA (CH) | 2009-05-26 | — | — | US | disclosed |
| US-20050148493-A1 | Indanes and indanones and their use in perfumery | FLACHSMANN FELIX (CH) | 2005-07-07 | — | — | US | disclosed |
| EP-1478616-A1 | INDANES AND INDANONES AND THEIR USE IN PERFUMERY | Givaudan SA (CH) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003072533-A1 | INDANES AND INDANONES AND THEIR USE IN PERFUMERY | GIVAUDAN SA (CH) | 2003-09-04 | — | — | WO | disclosed |
| EP-1340741-A1 | Indane derivatives and their use in perfumery | Givaudan SA (CH) | 2003-09-03 | — | — | EP | disclosed |
| US-6391991-B1 | USING COORDINATION POLYMERIZATION CATALYST | BASELL TECHNOLOGY COMPANY BV (NL) | 2002-05-21 | — | — | US | disclosed |
| EP-0693506-B1 | Process for the preparation of amorphous polymers of propylene | BASELL TECHNOLOGY CO BV (NL) | 2001-08-29 | — | — | EP | disclosed |
| EP-0693506-A2 | Process for the preparation of amorphous polymers of propylene | SPHERILENE S.p.A. (IT) | 1996-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029376-A1 | FUCOSIDASE INHIBITORS | FUCA1, FUCA2, ENGASE | ACHE 1591/4885METAP1 103/4885TSHR 2863/4885 |
| US-20050148493-A1 | Indanes and indanones and their use in perfumery | NISCH, CYP1B1, CYP2E1 | ACHE 295/4885METAP1 3939/4885TSHR 4768/4885 |
| US-20190077756-A1 | FUCOSIDASE INHIBITORS | FUCA1, FUCA2, ENGASE | ACHE 1591/4885METAP1 103/4885TSHR 2863/4885 |
| US-10308607-B2 | Fucosidase inhibitors | FUCA1, FUCA2, ENGASE | ACHE 1591/4885METAP1 103/4885TSHR 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.